Article
Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
Cancer immunology, immunotherapy : CII - 1 Jan 1990
Fortis C, Ferrero E, Besana C, Biffi M, Heltai S, Galli L, Borri A, Schoenheit A, Rugarli C
Abstract excerpt
The efficacy of recombinant interleukin-2 (rIL-2) or rIL-2 plus lymphokine-activated killer (LAK) cells in cancer therapy has been demonstrated by several groups both in experimental models in animals and clinical trials in humans, but their effects in vivo have yet to be clarified. Starting February 1988, we have treated 12 patients affected by advanced renal cancer with rIL-2 + LAK cells according to an open,...
Topics
- CD4 Antigens
- Carcinoma, Renal Cell
- Cell Division
- Drug Evaluation
- Humans
- Infusions, Intravenous
- Interleukin-2
- Kidney Neoplasms
- Killer Cells, Lymphokine-Activated
- Killer Cells, Natural